P-cell dysfunction in type 2 diabetes mellitus: the possibilities of modern antihyperglycemic therapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review reveals the current understanding of the role of в-cell dysfunction in the onset and development of type 2 diabetes mellitus (T2DM). The pathological processes underlying the impaired insulin secretion in T2DM are described. The data on the influence of modern antihyperglycemic therapy on the functional state of в-cells are presented.

Full Text

Restricted Access

About the authors

Natalia A. Chernikova

Russian Medical Academy of Continuous Professional Education

Cand. Sci. (Med.), Associate Professor at the Department of Endocrinology

References

  1. Ludvik B., Nolan J.J., Baloga J., Sacks D., Olefsky J. Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes. 1995;44:1121-25. Doi: 10.2337/ diab.44.9.1121.
  2. Polonsky K.S. Dynamics of insulin secretion in obesity and diabetes. Int J Obes Relat Metab Disord. 2000;24(Suppl. 2):S29-S31. Doi: 10.1038/ sj.ijo.0801273.
  3. Ferrannini E., Natali A., Bell P, et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100(5):1166- 73. doi: 10.1172/JCI119628.
  4. Tabak A.G., Jokela M., Akbaraly T.N., et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215-21. Doi: 10.1016/ S0140-6736(09)60619-X.
  5. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53(Suppl 3):S16-21. doi: 10.2337/diabetes.53.suppl_3.s16.
  6. Brown R.J., Rother K.I. Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. Pediatr Diabetes. 2008;9(3 Pt 2):14-22. doi: 10.1111/j.1399-5448.2007.00272.
  7. Ferrannini E. The stunned beta cell: a brief history. Cell Metab. 2010;11(5):349-52. Doi: 10.1016/j. cmet.2010.04.009.
  8. Butler A.E., Janso J., Bonner-Weir S., et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-10. doi: 10.2337/diabetes.52.1.102.
  9. Rahier J., Guiot Y., Goebbels R.M., et al. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10(Suppl. 34-42-42. doi: 10.1111/j.1463- 1326.2008.00969.x.
  10. Halban P.A., Polonsky K.S., Bowden D.W., et al. в -cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab. 2014;99(6):1983-92. doi: 10.1210/jc.2014-1425.
  11. Eizirik D.L., Cardozo A.K., Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocrinol Rev. 2008;29:42-61. Doi: 10.1210/ er.2007-0015
  12. Laybutt D.R., Preston A.M., Akerfeldt M.C., et al. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia. 4007;50:754-63. doi: 10.1007/300125-006-0590-z
  13. Tiedge M., LortzS., Drinkgern J., LenzenS. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes. 1997;46:1733-42. Doi: 10.2337/ diab.46.11.1733.
  14. Kruit J.K., Wijesekara N., Fox J.E., et al. Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules. Diabetes. 2011;60:3186-96. Doi: 10.2337/ db11-0081.
  15. Del Guerra S, Lupi R, Marselli L, et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes. 2005;54:727-35. doi: 10.2337/diabetes.54.3.727.
  16. Masters S.L., Dunne A., Subramanian S.L., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1b in type 2 diabetes. Nat Immunol. 2010;11:897-904. doi: 10.1038/ni.1935.
  17. Richardson S.J., Willcox A., Bone A.J., Foulis A.K., Morgan N.G. Islet-associated macrophages in type 2 diabetes. Diabetologia. 2009;52:1686-88. doi: 10.1007/s00125-009-1410-z
  18. Boni-Schnetzler M., Thorne J., Parnaud G., et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab. 2008;93:4065-74. doi: 10.1210/jc.2008-0396.
  19. Larsen C.M., Faulenbach M., Vaag A., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517-26. doi: 10.1056/NEJMoa065213.
  20. Robertson R.P, Harmon J., Tran PO., Tanaka Y., Takahashi H. Glucose toxicity in в-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52:581. doi: 10.2337/diabetes.52.3.581.
  21. Tabk A.G, Jokela M., Akbaraly T.N., et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215-21. doi: 10.1016/S0140-6736(09)60619-X.
  22. Russo G.T, Giorda C.B., Cercone S., et al. Beta cell stress in a 4-year follow-up of patients with type 2 diabetes: a longitudinal analysis of the BetaDecline Study. Diabetes Metab Res Rev. 2018;34(6):e3016. doi: 10.1002/dmrr.3016.
  23. Hou X., Liu J., Song J., et al. Relationship of Hemoglobin A1c with в Cell Function and Insulin Resistance in Newly Diagnosed and Drug Naive Type 2 Diabetes Patients. J Diabetes Res. 2016;2016:8797316. doi: 10.1155/2016/87973 1 6.
  24. Gleason C.E., Gonzalez M., Harmon J.S., Robertson R.P Determinants of glucose toxicity and its reversibility in the pancreatic islet betacell line, HIT-T15. Am J Physiol Endocrinol Metab. 2000;279:E997-1002. Doi: 10.1152/ ajpendo.2000.279.5.E997.
  25. Poitout V., Amyot J., Semache M., et al. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta. 2010;1801:289-98. doi: 10.1016/j.bbalip.2009.08.006.
  26. Cunha D.A., Hekerman., Cardozo A.K., Bellomo, E., et al. Initiation and execution of lipotoxic ER stress in pancreatic beta-cells. J Cell Sci. 2008;121:2308- 18. doi: 10.1242/jcs.026062.
  27. Weng J., Li Y, Xu W., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet 2008;371:1753-60. Doi: 10.1016/ S0140-6736(08)60762-X.
  28. Ashcroft F.M., Gribble F.M. ATP-sensitivi K+channels and insulin secretion: their role in health and disease. Diabetologia. 1999;2(8):903- doi: 10.1007/s001250051247.
  29. Bunck M.C., Diamant M., Corner A., et al. One-year treatment with exenatide improves betacell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32:762-68. doi: 10.2337/dc08-1797.
  30. Gerstein H.C, Bosch J., Dagenais G.R., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-28. doi: 10.1056/NEJMoa1203858.
  31. Mcinnes N., Hall S., et al. 677-P: Remission of Type 2 Diabetes following Intensive Treatment with Insulin Glargine, Lixisenatide, Metformin, and Lifestyle Approaches: Results of a Multicenter Randomized Controlled Trial. Diabetes. 2021;70(Supplement 1):677-P Doi:10.2337/ db21-677-P.
  32. Xu W., Li Y.B., Deng W.P, Hao Y.T., Weng J.P Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. Chinese Med Jio2009;122:2554-59.
  33. Retnakaran R., Zinman B. Short-term intensified insulin treatment in type 2 diabetes: longterm effects on beta-cell function. Diabetes Obes Metab 00J0;J4(Suppl doi: 10.1111/j.1463-1326.2012.01658.x.
  34. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43. doi: 10.1056/NEJMoa066224.
  35. Patane G., Piro S., Rabuazzo A.M., et al. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2000;49:735-40. Doi: 0.2337/ diabetes.49.5.735.
  36. Simon-Szabo L., Kokas M., Mandl J., et al. Metformin attenuates palmitate induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells. PLoS One. 2014;9:e97868. doi: 10.1371/journal.pone.0097868.
  37. DeFronzo R.A., Tripathy D., Schwenke D.C., et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104-doi: 10.1056/NEJMoa1010949.
  38. Lupi R., Del Guerra S., Marselli L., et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab. 6004;286:E560-61.Doi: 10.1152/ ajpendo.00561.2002.
  39. Russo G.T., Giorda C.B., Cercone S., et al. Factors associated with beta-cell dysfunction in type 2 diabetes: the BETADECLINE study. PLoS One. 2014;9(10):e109702. doi: 10.1371/jEurnal. pEne.0109702.
  40. Maedler K., Carr R.D., Bosco D., et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 0--5;9-:5-1-4. doi: 10.1210/jc.2004-0699.
  41. UK Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58. doi: 10.2337/diab.44.11.1249.
  42. Kahn S.E., Lachin J.M., Zinman B., et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes. 0-JJ;4-:J550-4-. Doi: 10.2337/ db10-1392.
  43. Drucker D.J., Philippe J., S., et al. Glucagon like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. ProcNatl Acad Sci USA. 1987;84:3434-38. doi: 10.1073/pnas.84.10.3434.
  44. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270-76. Doi: 10.2337/ diabetes.48.12.2270.
  45. Farilla L., Bulotta A., Hirshberg B., et al. Glucagonlike peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149-58. doi: 10.1210/en.2003-0323.
  46. Derosa G., Carbone A., DAngelo A., et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and beta-cell function. Expert Opin PhormocECher. 2-12;13:2433-42. doi: 10.1517/14656566.2012.730519.
  47. Ohkura T., Fujioka Y., Sumi K., et al. Sitogliptin improves the impaired acute insulin response during a meal tolerance test in Japanese patients with type 2 diabetes mellitus: a small-scale real-world study. Diabetes Ther. 2014;5:285-97. doi: 10.1007/s13300-014-0071-1.
  48. Cunha D.A, Ladriere L, Ortis F., et al. Glucagon like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes. 2009;58:2851-62. doi: 1-.2337/db-9--485.
  49. NotolicchiE A., Labarbuta R., TErtEso F, et al. Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway. 6iobetEbgio. 2-J3;56:2456-66. doi: 10.1007/s00125-013-3028-4.
  50. Shimo N., Matatoua T.A., Miyotsuko T., et al. Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key beta-cell factors under diabetic conditions. Biochem Biophys Res Commun. 2015;467:948-doi: 10.1016/j.bbrc.2015.10.038.
  51. Okauchi S., Shimoda M., A., et al. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in obese type 0 diabetic db/db mice. Biochem Biophys Res Commun. 2-J4;47-:772-82. Doi: 10.1016/j. bbrc.2015.10.109.
  52. Rosenstock J., Aggarwal N., D., et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 0-J0;35:J030-38. Doi: 10.0337/ dc11-1926.
  53. Matthews D.R., Paldanius PM., P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 0 diabetes (VERIFY): A 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394:1519-29. Doi: 10.1016/ S0140-6736(19)32131-2.
  54. Meier J.J., Schenker N., Kahle M., et al. Impact of insulin glargine and lixisenotide on в-cell function in patients with type 2 diabetes mellitus: A randomized open-label study. Diabetes Obes Metab. 2017;19(11):1625-29. Doi: 10.1111/ dom.10968.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies